Using our novel inhibitor, MDI-2517, and two different models of lung fibrosis, we show that PAI-1 inhibition has a dose dependent effect on the severity of scarring with a maximal benefit observed at doses of 60 mg/kg and above. Here, SERPINE1 is linked to pulmonary fibrosis.